Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Esperion Therapeutis.Inc. diskutieren

Esperion Therapeutis.Inc.

WKN: A1W1SJ / Symbol: ESPR / Name: Esperion / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

3,30 €
0,40 %

15 0
15
0
Einschätzung Buy
Rendite (%) -59,58 %
Kursziel 7,46
Veränderung
Endet am 28.06.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
28.06.24
Einschätzung Buy
Rendite (%) -12,46 %
Kursziel 14,63
Veränderung
Endet am 12.08.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
12.08.24
Einschätzung Buy
Rendite (%) -4,42 %
Kursziel 5,48
Veränderung
Endet am 13.08.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at Needham & Company LLC from $8.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
13.08.24
Einschätzung Buy
Rendite (%) 47,25 %
Kursziel 14,48
Veränderung
Endet am 02.10.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
02.10.24

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat

StockNews.com 
0
Melden Teilen
05.10.24 Buy 41,81 %

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat

StockNews.com 
0
Melden Teilen
26.10.24 Buy 18,51 %
Einschätzung Buy
Rendite (%) 8,13 %
Kursziel 14,88
Veränderung
Endet am 08.11.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
08.11.24
Einschätzung Buy
Rendite (%) 11,73 %
Kursziel 15,13
Veränderung
Endet am 19.11.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
19.11.24
Einschätzung Buy
Rendite (%) 41,18 %
Kursziel 15,13
Veränderung
Endet am 27.11.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
27.11.24
Einschätzung Buy
Rendite (%) 7,59 %
Kursziel 15,20
Veränderung
Endet am 03.12.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
03.12.24
Einschätzung Buy
Rendite (%) 33,81 %
Kursziel 15,24
Veränderung
Endet am 12.12.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
12.12.24
Einschätzung Buy
Rendite (%) 57,58 %
Kursziel 5,71
Veränderung
Endet am 13.12.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
13.12.24
Einschätzung Buy
Rendite (%) 36,98 %
Kursziel 7,61
Veränderung
Endet am 17.12.25

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Cantor Fitzgerald 
0
Melden Teilen
17.12.24

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
10.01.25 Buy 58,28 %
Einschätzung Buy
Rendite (%) 60,13 %
Kursziel 15,36
Veränderung
Endet am 23.01.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
23.01.25
Einschätzung Buy
Rendite (%) 92,19 %
Kursziel 15,49
Veränderung
Endet am 11.02.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
11.02.25
Einschätzung Buy
Rendite (%) 97,60 %
Kursziel 15,20
Veränderung
Endet am 04.03.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
04.03.25
Einschätzung Buy
Rendite (%) 121,57 %
Kursziel 14,67
Veränderung
Endet am 20.03.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
20.03.25
Einschätzung Buy
Rendite (%) 214,00 %
Kursziel 4,56
Veränderung
Endet am 08.04.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
08.04.25
Einschätzung Buy
Rendite (%) 326,74 %
Kursziel 4,41
Veränderung
Endet am 25.04.26

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
25.04.25
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

HC_Wainwright in Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price targ...
17:15
Evercore_ISI in Essential Properties Realty Trust diskutieren
Essential Properties Realty Trust (NYSE:EPRT) was given ...
16:30
Jefferies_Financial_ in Associated British Foods ADR diskutieren
Associated British Foods (OTCMKTS:ASBFY) was downgraded ...
16:30
Roth_Capital in Atkore International Group Inc diskutieren
Atkore (NYSE:ATKR) had its "buy" rating reaffirmed by an...
16:15
Truist_Financial_Co_ in WAVE Life Sciences Ltd diskutieren
WAVE Life Sciences (NASDAQ:WVE) was given a new $50.00 p...
16:01
HC_Wainwright in Stoke Therapeutics Inc diskutieren
Stoke Therapeutics (NASDAQ:STOK) had its price target rai...
15:15
JPMorgan_Chase___Co_ in Insight Enterprises diskutieren
Insight Enterprises (NASDAQ:NSIT) had its "underweight" ...
15:15
Clarkson_Capital in Tenneco Inc. diskutieren
Tsakos Energy Navigation (NYSE:TEN) is now covered by an...
15:15
Mehr anzeigen